DE60045243D1 - VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN - Google Patents

VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN

Info

Publication number
DE60045243D1
DE60045243D1 DE60045243T DE60045243T DE60045243D1 DE 60045243 D1 DE60045243 D1 DE 60045243D1 DE 60045243 T DE60045243 T DE 60045243T DE 60045243 T DE60045243 T DE 60045243T DE 60045243 D1 DE60045243 D1 DE 60045243D1
Authority
DE
Germany
Prior art keywords
domains
generating
materials
binding characteristics
adjusted binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045243T
Other languages
English (en)
Inventor
Kalle Saksela
Marita Hiipakka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Next Biomed Technologies NBT Oy
Original Assignee
Next Biomed Technologies NBT Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies NBT Oy filed Critical Next Biomed Technologies NBT Oy
Application granted granted Critical
Publication of DE60045243D1 publication Critical patent/DE60045243D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Graft Or Block Polymers (AREA)
  • Ceramic Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Photoreceptors In Electrophotography (AREA)
DE60045243T 1999-05-26 2000-05-26 VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN Expired - Lifetime DE60045243D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13608599P 1999-05-26 1999-05-26
PCT/FI2000/000477 WO2000072742A2 (en) 1999-05-26 2000-05-26 Methods and materials for generating sh3 domains with tailored binding properties

Publications (1)

Publication Number Publication Date
DE60045243D1 true DE60045243D1 (de) 2010-12-30

Family

ID=22471216

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60045243T Expired - Lifetime DE60045243D1 (de) 1999-05-26 2000-05-26 VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN

Country Status (9)

Country Link
US (1) US6794144B1 (de)
EP (1) EP1181358B1 (de)
JP (1) JP2003500080A (de)
AT (1) ATE488584T1 (de)
AU (1) AU4761100A (de)
CA (1) CA2374180C (de)
DE (1) DE60045243D1 (de)
ES (1) ES2371464T3 (de)
WO (1) WO2000072742A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109532C1 (de) * 2001-02-28 2002-06-13 Matthias Geyer Fusionsprotein zum Blocken des HIV Nef-Proteins
WO2002083846A2 (en) * 2001-04-10 2002-10-24 Children's Medical Center Corporation Methods of analysis and labeling of protein-protein interactions
EP1814575A4 (de) * 2004-11-24 2010-07-07 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von leiden
EP2015765A4 (de) * 2006-03-28 2011-11-23 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von erkrankungen
EP1930342B1 (de) 2006-12-04 2012-01-25 Institut Pasteur Als Gerüst verwendeter OB-Fold zur Entwicklung neuer spezifischer Bindemittel
EP2152725A1 (de) * 2007-05-17 2010-02-17 Neopro Labs, LLC Kristalline und amorphe peptidformen
US20090069237A1 (en) * 2007-07-18 2009-03-12 Hanna Skubatch Methods and compositions for treating conditions
CN110922467A (zh) 2013-01-17 2020-03-27 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
JP6743022B2 (ja) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド 免疫療法のためのナノ粒子組成物及び方法
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method of Preparation of a Library comprising Recombinant Derivatives of the SH3 Domain of Nephrocystin (NPHP1)
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
MX2018006194A (es) 2015-11-19 2018-12-06 Asclepix Therapeutics Llc Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas.
CN117024599A (zh) 2016-02-05 2023-11-10 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CN110177563A (zh) 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
EP3576765A4 (de) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. Zielgerichtetes manipuliertes interferon und verwendungen davon
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3580230A1 (de) 2017-02-07 2019-12-18 VIB vzw Auf immunzellen gerichtete bispezifische chimäre proteine und verwendungen davon
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
AU2019215440A1 (en) 2018-02-05 2020-08-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
BR112021016056A2 (pt) 2019-02-15 2021-12-14 Integral Molecular Inc Anticorpos de claudina 6 e usos dos mesmos
EP3924379A4 (de) 2019-02-15 2022-12-21 Integral Molecular, Inc. Antikörper mit einer gemeinsamen leichten kette und deren verwendungen
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
WO2023089243A1 (en) * 2021-11-19 2023-05-25 Pandemblock Oy Sh3 domain derivatives targeting receptor binding domain (rbd) of sars-cov-2 spike protein
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0750630A4 (de) 1994-03-11 1998-01-07 Ariad Pharma Inc Methode und materialien zur identifizierung von inhibitoren der molekularen interaktionen, welche durch die sh3 domänen vermittelt werden
WO1996003649A1 (en) * 1994-07-22 1996-02-08 The University Of North Carolina At Chapel Hill Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME
EP0833941B1 (de) * 1995-04-07 2008-10-22 Cytogen Corporation Polypeptide mit spezieller, funktioneller domäne, verfahren zu ihrer identifikation und anwendungen derselben

Also Published As

Publication number Publication date
CA2374180C (en) 2012-09-11
EP1181358B1 (de) 2010-11-17
CA2374180A1 (en) 2000-12-07
WO2000072742A3 (en) 2001-02-22
WO2000072742A2 (en) 2000-12-07
AU4761100A (en) 2000-12-18
ATE488584T1 (de) 2010-12-15
EP1181358A2 (de) 2002-02-27
US6794144B1 (en) 2004-09-21
JP2003500080A (ja) 2003-01-07
ES2371464T3 (es) 2012-01-03

Similar Documents

Publication Publication Date Title
DE60045243D1 (de) VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
DE69839451D1 (de) Prozess zur herstellung und anwendung von anionischen lehm materialien
EP1408986A4 (de) Proteomimetische verbindungen und verfahren
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
TW200603830A (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
HK1008230A1 (en) Tie-2 ligands, methods of making and uses thereof.
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
BR9709015A (pt) Quinolina carboxamidas como inbidores de tnf e como inbidores de pde-iv
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
DE60334995D1 (de) Verfahren zur herstellung von amorphen und keramischen stoffen mittels schmelzspinnen
MX9706827A (es) Activacion de receptor por gas6.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
WO2004094614A3 (en) Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
WO1999051263A3 (en) Methods and modified cells for the treatment of cancer
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE372962T1 (de) Synthetische silikatpelletzusammensetzung, verfahren zu dessen herstelung und dessen anwendung
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen